CellCarta supports biomarker quantification through several platforms,selected based on your study's requirements. Key options include LC-MS/MS using MRM or PRM assays,and immunoassays such as Olink®,MSD®,and Ella™. Our scientific team will help identify the most relevant platform for your program.
"},{"faq_question":"How can your biomarker quantification services adapt to my study?","faq_answer":"The platform and analysis workflow for biomarker quantification are tailored to your study’s specifications,taking sample matrix,biology,and endpoint strategy into account. This ensures the right platform is selected for your program,avoiding unnecessary experimentation and keeping your timelines on track.
"},{"faq_question":"What panels are offered for biomarker quantification?","faq_answer":"We offer a range of validated OTS panels,including assays for BCMAs,targeted protein degraders (TPDs),and key proteins associated with several neurological pathologies. These panels are compatible with several biological matrices,including serum,plasma,tissue,and more. Custom assay and panel development is also available for programs with specific biomarker testing requirements.
"},{"faq_question":"What is immuno-MRM and when is it used?","faq_answer":"Immuno-MRM is an immunoaffinity enrichment approach coupled to LC-targeted MRM,enabling sensitive and precise protein quantification. This assay supports multiplexing and can detect post-translational modifications (PTMs),making it suitable for large-scale biomarker testing. CellCarta offers several validated immuno-MRM panels covering DNA damage response,immuno-oncology,Ras-MAPK signaling,and HER2 expression. New panels with up to 50 protein targets can also be developed for client-specific needs.
"},{"faq_question":"Are your biomarker quantification services GCLP-compliant?","faq_answer":"Yes. All assay development and validation protocols follow GCLP compliance standards,and services are delivered through CAP-accredited and CLIA-certified laboratory sites. Our assays and SOPs also undergo rigorous QA/QC review and align with CPTAC standards,ensuring they are ready for integration into clinical trials and regulatory submissions.
"}]}#-supreme-cellcarta-service-blocks-8-708{blocks-data:[{"image":"https://cellcarta.com/wp-content/uploads/2026/06/Receptor-Occupancy-tab-48.jpg","image_alt":"Mass spectrometry platform for scalable proteomic monitoring and bioanalysis","title":"Mass Spectrometry","description":"Scalable proteomic monitoring and bioanalysis under GCLP and QC conditions.","button_text":"Discover","button_url":"/platforms/mass-spectrometry/","button_target":"_self"},{"image":"https://cellcarta.com/wp-content/uploads/2026/06/Immunoassay-Services-hero-9.jpg","image_alt":"Validated immunoassay platforms for precise biomarker quantification and clinical testing","title":"Immunoassay Platforms","description":"Validated immunoassay platforms for precise biomarker quantification and clinical testing.","button_text":"Discover","button_url":"/capabilities/immunoassay-services/","button_target":"_self"},{"image":"https://cellcarta.com/wp-content/uploads/2026/06/Clinical-application-86.jpg","image_alt":"LC-MS/MS unbiased discovery proteomics for novel biomarker identification","title":"Unbiased Discovery","description":"LC-MS/MS for novel biomarker identification.","button_text":"Discover","button_url":"/capabilities/proteomics/unbiased-discovery/","button_target":"_self"}]}#-supreme-cellcarta-tab-content-4-708{oxy-supreme-cellcarta-tab-content-content-heading-tag:h3;oxy-supreme-cellcarta-tab-content-content-heading-size:default;oxy-supreme-cellcarta-tab-content-content-body-size:default;tabs-data:[{"tab_title":"Platform Agnostic","content_title":"","content_body":"Our platform agnostic workflow is designed to your study’s specifications,and our scientists can consult your team on the best platform for bioanalysis,which can include:
\nAutomation is incorporated into our sample processing workflows to ensure rapid turnaround time and reproducibility.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-31-2-scaled.jpg","image_alt":"Scientist using platform-agnostic biomarker quantification workflow in CellCarta laboratory"},{"tab_title":"Clinical Matrices","content_title":"","content_body":"Our experts have vast experience handling a wide range of biological matrices,including:
Letting your study requirements,including sample type,drive platform selection will optimize our analytical approach to support the overall success of your clinical trial.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Clinical-Matrices-142.jpg","image_alt":"Clinical sample types supported for biomarker quantification including serum,plasma,and tissue"},{"tab_title":"OTS Panels","content_title":"","content_body":"Using validated off-the-shelf (OTS) panels,we can perform biomarker testing for a variety of sample types,including:
\nContact us to learn more about our OTS offerings.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/OTS-Panel-Offerings-24.jpg","image_alt":"Validated off-the-shelf biomarker panels for BCMA,TPD targets,and CNS disease proteins"},{"tab_title":"Custom Development","content_title":"","content_body":"When your study needs more,our team has the expertise to develop custom biomarker quantifications assays that undergo rigorous fit-for-purpose validation.
\nAll protocols used are GCLP-compliant and adhere to CPTAC guidelines,ensuring these panels can be seamlessly integrated into your clinical trial at any stage of development.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Custom-Development-118.jpg","image_alt":"CellCarta scientist developing custom biomarker quantification assay with fit-for-purpose validation"}]}